Weave’s cover photo
Weave

Weave

Biotechnology Research

The new standard in regulatory automation and lifecycle management

About us

Weave Bio is an AI-native regulatory automation management platform redefining regulatory submissions for novel therapeutic candidates. Designed for pharma, biotechs, CROs, and consultants, the Weave Platform streamlines regulatory document preparation and lifecycle management by automating initial draft documents, extracting key insights, and integrating study data into a seamless, AI-enabled workflow. The platform accelerates regulatory processes, enabling faster drafting, high-quality reviews, and compliance with global standards. AutoIND, widely adopted for preclinical IND submissions, earned the “Biotech AI Innovation of the Year” award. And with AutoCT, Weave expanded capabilities into clinical-stage submissions, building the foundation for a singular AI workbench for the entire therapy lifecycle. Backed by top investors in AI and life sciences, Weave is creating a new AI-enabled, human-driven platform to enhance efficiency, submission quality, and cost-effectiveness. For more information, visit weave.bio

Industry
Biotechnology Research
Company size
11-50 employees
Type
Privately Held
Founded
2023

Employees at Weave

Updates

  • View organization page for Weave

    2,300 followers

    🚀 Regulatory teams deserve a unified solution, not a patchwork of disconnected tools. With Weave, Regulatory has one home. Weave is pioneering the first AI-native regulatory automation management platform, providing a single source of truth for the entire regulatory lifecycle—from early development to approval and beyond. Through automation, intelligent data integration, and streamlined workflows, Weave empowers teams to focus on strategy rather than manual document preparation. 📢 On the latest AI in Action podcast, Brandon Rice, our Chief Product Officer, joins JP Valentine to discuss how Weave is transforming regulatory operations: ✅ A full-solution platform for the entire regulatory lifecycle, not just submissions ✅ AI-powered automation to simplify filings, reduce costs, and accelerate approvals ✅ Scalable, collaborative tools that empower teams to focus on strategy, not paperwork 🎧 Listen now: https://lnkd.in/eWEr_tbv or wherever you get your favorite podcasts! Want to learn more about how Weave can transform your regulatory operations? Contact us at [email protected]. #AIinAction #RegulatoryAutomation #RegulatoryLifecycle #AIpowered #Weave

    AI in Action E548: Brandon Rice, Chief Product Officer at Weave - Alldus

    AI in Action E548: Brandon Rice, Chief Product Officer at Weave - Alldus

    https://alldus.com

  • 🗓️ Mark your calendars! Our Chief Product Officer, Brandon Rice, joins JP Valentine on The Alldus Podcast: AI in Action next Monday! 🎙️ Brandon shares how Weave is redefining regulatory submission workflows and what’s next as we push the boundaries of drug development with our AI-native regulatory automation platform. We’re just getting started, and big things are ahead! 🔊 Catch a sneak peek now and tune in for the full episode dropping 02/24 at alldus.com/podcasts or wherever you listen to podcasts! #AIinAction #AIinPharma #AIinBiotech #Podcasts #AIinRegulatory

    View organization page for Alldus

    113,281 followers

    Don't miss next Monday's brand new episode in our AI in Action series of The Alldus Podcast when host JP Valentine will be joined by Brandon Rice, Chief Product Officer at Weave. Check out this short teaser as Brandon highlights their focus on growth, fundraising and customer traction to accelerate drug development, while also refining the product and reaching their next funding milestone. Full episode drops 02/24 so stay tuned to alldus.com/podcasts or wherever you get your favorite podcasts so you don't miss it #aiinaction #productdevelopment #drugdevelopment #podcasts

  • View organization page for Weave

    2,300 followers

    The First Step to Publishing in #AutoIND with Always-On Links Linking throughout the dossier is an integral step in preparing your regulatory documents for submission. In AutoIND, you may now create links with a few keystrokes as you draft. Those links always remain up-to-date, even as you add new sections or tables. Easy to make and effortless to maintain, the way links were meant to be. 🔗 Link to tables, figures, and sections with a few keystrokes ✅ Links always remain current: functional and with appropriate label text 📂 Link to any source document from your data room, including scientific literature 👉 See AutoIND in action. Get in touch with us at: [email protected]. #AIinpharma #AIinbiotech #AIinRegulatory #RegulatoryAffairs #WeaveWednesday

  • 🚨 In Case You Missed It: This Week at FDA Our friends at Regulatory Affairs Professionals Society (RAPS) released their weekly FDA update on Friday, covering the latest regulatory shifts and industry-impacting news. This edition dives into key developments, including major leadership changes and policy updates that could have significant effects across biotech and pharma. Staying informed is critical in a fast-moving regulatory landscape—don’t miss out on the latest insights. 🔗 Read the full update here: https://lnkd.in/gsfsdACn #RegulatoryAffairs #FDAUpdates #LifeSciences #AIinBiotech #AIinPharma

    This Week at FDA: Trump fires thousands of federal workers, Kennedy sworn in as HHS secretary, and more

    This Week at FDA: Trump fires thousands of federal workers, Kennedy sworn in as HHS secretary, and more

    raps.org

  • View organization page for Weave

    2,300 followers

    We ❤️ AI Roses are red, Violets are bright, Weave’s AI workbench Helps get submissions done right!  💡🤖 This Valentine’s Day, we’re swooning over our AI-native regulatory automation management platform—saving time, boosting efficiency and making drug regulatory work a little more lovable!💕✨ 💬 Tag someone who loves AI as much as we do! 💙 #ILoveAI #ValentinesDay #AIinpharma #AIinbiotech #AIinRegulatory #WeaveBio

    • No alternative text description for this image
  • View organization page for Weave

    2,300 followers

    📢 #AutoIND February Release: Data Exploration ➡️ Publishing Our February release is just the thing to shake you out of the January doldrums. We're significantly extending workflow support with Publishing v1 and Data Exploration, covering both earlier and later stages of your submission workflow. Content quality is also getting a big boost with Data Tags, offering greater precision and flexibility when mapping source data to templates. Highlights: 🔗 Add links throughout the dossier that always stay up-to-date 📄 Better first drafts and more powerful templates with Data Tags (especially in CMC/Module 3) 📊 Instantly tabulate your entire Data Room however you wish with the new Data Room Overview ❓ Ask any question of your source documents and get your answer as a summary, table, list, or letter …and more! ➡️ Review the full release here: https://lnkd.in/g8XjcfCs #WeaveWednesday #AIinPharma #AIinBiotech #AIinRegulatory #AIinnovation #regulatoryautomation

  • View organization page for Weave

    2,300 followers

    👨🍳 Document creation just got a Michelin star upgrade! Shoutout to our CPO, Brandon Rice, for the inspiration behind this spicy take!🌶️ Using LLMs is like trading in endless prep work for full creative control in the kitchen. No more spending all day slicing and dicing data. Now you get to plan the menu (strategize), create signature dishes (generate insights), and perfect the flavors (refine your story). LLMs aren’t just tools; they’re your new AI sous-chefs 👩🍳, helping you serve up success with flair and consistency. 🔥 Hungry to learn more? Connect with us at [email protected]. Let's cook up something great together! 🍽️

    View profile for Brandon Rice

    CPO @ Weave | Reimagining Regulatory

    Creation of documents (like regulatory submissions) with LLMs is like going from line cook to head chef. Rather than spending all day peeling vegetables (extracting data), cooking stock (building tables), and chopping ingredients (drafting summaries), you can focus on planning the menu (devising strategy), inventing new dishes (interpreting data), and honing flavors (refining a narrative). In both cases the result is a product of your choices and judgement. The difference is leverage: a chef's team can crank out a hundred dishes a night with unfailing consistency. Not to mention that the tasting and tweaking is just a lot more fun 🙂.

  • View organization page for Weave

    2,300 followers

    Wow! What an incredible time we had at #RSIDM25! 🎉 A huge thank you to everyone who stopped by and engaged with us—your energy and curiosity made this event unforgettable! 💬🙌 Special shout out to DIA for organizing such an informative and inspiring event. If you left wanting more, there’s plenty for us to explore together: ✔️ Weave platform capabilities – See how we support your IND and regulatory journey ✔️ Our study design and early results – Accelerating data-driven decisions and timelines ✔️ #Quality measures/rubric suggestions – Raising the bar with innovative best practices ✔️ Partnership opportunities – Collaborating for mutual success We'd love to keep the momentum going! 📧 Reach out to schedule time or request follow-up information: [email protected] #DIA #RSIDM25 #WeaveInnovation #regualtoryoperations

    • No alternative text description for this image
  • View organization page for Weave

    2,300 followers

    Weave Wednesday: Reflecting & Projecting (pt 2) Today, we're sharing the second part of a personal message from our CPO, Brandon Rice, about what's ahead for Weave. "Reflecting and Projecting (pt. 2)" The beauty of starting with the IND is that it lays the foundation for everything that follows. IND clearance begets more studies, bigger batches, and tighter timelines; but it’s all eCTD at the end of the day (in the US). Moreover, every regulatory submission follows the same core workflow that we established under the IND: upload, draft, refine, review, QC, publish. So we need not build a brand new platform for each document, we can simply extend the platform we already have. So what’s the plan for 2025? The natural progression after building a product for the very first regulatory submission in a drug’s life is to build the products for the rest of them. And that’s what we intend for this year: to enable the rest of the regulatory lifecycle on the Weave Platform. Concretely, that means clinical-phase filings. Clinical study reports, protocols, and amendments to start. Safety reports, annual reports, and (improved) IB’s to follow. We aim to cap the year going beyond the clinic to NDA’s and BLA’s, but we prefer to under promise and over deliver, so I’ll come back to you on that in six months. We are not on this journey alone. We are building for you, our customers. There is less hand-wringing these days about AI taking jobs, and for good reason. Human experience and judgment, especially in drug development, is irreplaceable. But the jobs themselves will inevitably transform, and that is happening as we speak. Come join us in shaping a new paradigm for the therapeutic regulatory lifecycle. Brandon Rice Chief Product Officer #WeaveWednesday  #AIinpharma #AIinbiotech #AIinRegulatory

    • No alternative text description for this image
  • 🚀 Day 2 at DIA RDISM – Don’t Miss Our Talk! Day 1 was packed with incredible conversations and energy, and Day 2 is shaping up to be just as exciting! Today, we’re thrilled to present our session on Evaluating Time Savings in Regulatory Writing, featuring preliminary insights from a study with a top 20 pharma company. 🕒 Time: 10:05 - 10:35 AM 📍 Location: Forest Glen Room (lower level) After the talk, stop by Booth #100 to continue the conversation, explore how Weave can support your goals, and create your own AI caricature! See you soon at DIA RDISM! #RDISM2025 #RegulatoryInnovation #DIA

    • No alternative text description for this image

Similar pages

Browse jobs

Funding

Weave 3 total rounds

Last Round

Seed

US$ 10.0M

See more info on crunchbase